Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets

Ya-Hui Ding; Yuan Ma; Lin-Yan Qian; Qiang Xu; Li-Hong Wang; Dong-Sheng Huang; Hai Zou

doi:10.18632/oncotarget.19522

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets

Ya-Hui Ding, Yuan Ma, Lin-Yan Qian, Qiang Xu _, Li-Hong Wang, Dong-Sheng Huang and Hai Zou

PDF | HTML | How to cite

Oncotarget. 2017; 8:60673-60683. https://doi.org/10.18632/oncotarget.19522

Metrics: PDF 1707 views | HTML 3191 views | ?

Abstract

Ya-Hui Ding1,3, Yuan Ma1,3, Lin-Yan Qian1,3, Qiang Xu1,3, Li-Hong Wang1,3, Dong-Sheng Huang2,3 and Hai Zou1,3

1Department of Cardiology, Zhejiang Provincial People's Hospital, Hangzhou 310014, China

2Department of Hepatobiliary Surgery, Zhejiang Provincial People's Hospital, Hangzhou 310014, China

3People’s Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China

Correspondence to:

Qiang Xu, email: [email protected]

Li-Hong Wang, email: [email protected]

Dong-Sheng Huang, email: [email protected]

Hai Zou, email: [email protected]

Keywords: non-alcoholic fatty liver disease, atrial fibrillation, adiponectin, insulin resistance, renin angiotensin aldosterone system

Received: May 23, 2017 Accepted: July 13, 2017 Published: July 24, 2017

ABSTRACT

Non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) are common chronic non-infectious diseases with rising incidences. NAFLD is an independent risk factor for the onset of AF, after adjusting potentially related factors. The pathogenesis of these diseases share several mechanisms including reduced adiponectin level, insulin resistance, and renin angiotensin aldosterone system (RAAS) activation, in addition to activation of common disease pathways that promote inflammation, oxidative stress, and fibrosis. Furthermore, statins and RAAS blockers exert therapeutic effects concurrently on NAFLD and AF. The common pathogenesis of NAFLD and AF may serve as a potential therapeutic target in the future.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19522

Publication Alerts

Reviews:

Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets

Abstract